XTL Biopharma files to raise $40m on Nasdaq
Insightec develops MRI-guided focused ultrasound devices for the treatment of uterine fibroids, tumors, and neurological disorders.
GE Healthcare has invested $13.75 million in InSightec Image Guided Treatment Ltd. in the form of a convertible loan. Insightec develops MRI-guided focused ultrasound devices for the treatment of uterine fibroids, tumors, and neurological disorders, such as essential tremor‚ neuropathic pain and Parkinson’s disease.
Insightec has been marketing its non-invasive device for the treatment of uterine fibroids for years, but the company is still not profitable, and sales are stagnant. Insightec said that it would use the proceeds to finance its development plan for 2012 in R&D, sales and marketing, customer support, and financing legal costs in cases filed against it.
The loan will bear 6% interest, and can be converted into equity at a price set when a new partner invests in Insightec, or when the loan matures in 2016. Given that Elbit Medical Technologies Ltd. (TASE:EMTC), controlled by Mordechay Zisser, have tried to keep their stakes in the company, the loan will apparently be converted in the event of an exit or strategic marketing agreement, possibly by GE Healthcare itself. It is also possible that the companies believe that such an event will happen before 2016.
Insightec and GE Healthcare have been collaborating since the 1990s. Until 2007, GE held a minority stake in Insightec through GE Capital, and, together with Elbit Medical, made regular investments in the company to maintain its stake. Insightec's devices were adapted to GE's MRI devices, and marketed as a complete product.
GE Healthcare last invested in Insightec in 2008. The new investment is directly into the company, rather than through Elbit Medical, suggesting the strategic importance that GE attaches to the investment.
The investment comes as Zisser faces problems. Zisser's real estate company, Elbit Imaging Ltd. (Nasdaq: EMITF; TASE: EMIT), which owns 90% of Elbit Medical, faces severe liquidity problems. Although Elbit Imaging has promised a NIS 39 million credit line to Elbit Medical, which has promised a NIS 58 million credit line to Insightec, it is convenient for them if the loans are not requested. Elbit Medical had just $658,000 in cash at the end of September 2011.
GE Healthcare's loan is at the same terms as in loans by Elbit Medical to Insightec. The loans are secured by a floating lien on Insightec's assets. Elbit Imaging has lent Insightec NIS 130 million in loans over the years, and it will probably maintain its stake in Insightec, even if GE Healthcare converts its loan into equity.
Elbit Medical's share price fell 2.7% by mid-afternoon to NIS 0.216, giving a market cap of NIS 174 million.
Published by Globes [online], Israel business news - www.globes-online.com - on February 26, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012
You comment was recieved and soon will be published.
Load more comments
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.